BRIEF-Oxford Bio to close prostate cancer study in U.S.

LONDON, Oct 10 (Reuters) - Oxford BioMedica PLC :

* To close phase II study in US to assess Trovax in patients with prostate


* Continues to have an active phase II development programme in other

indications in UK

* Prostate cancer treatment landscape in the US has changed with new products available and other clinical trials targeting the same indication

* Competition for suitable patients has been high and recruitment into US study has been much slower than originally anticipated

((London Equities Newsroom; +44 20 7542 7717))

((For more news, please click here ))